New mRNA Therapy Shows Promise for Preventing Type 1 Diabetes
Researchers have made a significant breakthrough with a new mRNA therapy that might help prevent or slow the onset of type 1 diabetes. This chronic autoimmune disease occurs when the body’s immune system attacks the insulin-producing beta cells in the pancreas. Individuals diagnosed with type 1 diabetes need to take insulin daily to manage their blood sugar levels.
A team from the University of Chicago, aiming to prevent this condition that affects about 1.9 million people in the United States, has developed a “nanoparticle” system. This innovative method delivers genetic instructions directly to the insulin-producing cells.
When the mRNA enters these cells, it prompts them to produce PD-L1, a protein that can shield against immune system attacks. Researchers have highlighted that PD-L1 is effective in preventing autoimmune diseases and limiting inflammation and damage to healthy tissues during infections.
In initial animal trials, the nanoparticles successfully reached their target cells, demonstrating a protective effect. The results were also encouraging in models where human beta cells were transplanted into mice.
The study was published in the journal Cell Reports Medicine. Lead author Jacob Enriquez, a postdoctoral scholar at the University of Chicago, expressed excitement over the results. “We successfully delivered PD-L1 mRNA using our nanoparticle system, which delayed the progression of type 1 diabetes in mice. This approach also shows potential relevance for human cells,” he said.
While the findings are promising, researchers emphasize that further tests are necessary to ensure the therapy’s safety, proper dosage, and effectiveness before moving to human trials. This initial research was conducted in laboratory and animal models and did not assess long-term safety or the duration of the protection offered.
If further studies confirm the results in humans, this method could provide a new way to protect insulin-producing cells and possibly delay or prevent type 1 diabetes. Current preventative approaches often involve broad changes to the immune system to slow down the autoimmune attack on these crucial cells.
Co-author Raghu G. Mirmira, who directs the UChicago Diabetes Research and Training Center, noted the exciting potential of this study. “We’re looking at a new way to engineer beta cells, aiming to target specific cell types without affecting others,” he stated.
The research received funding from Breakthrough T1D and the National Institutes of Health. If all goes well in future studies, this advance could change the landscape for those at risk of type 1 diabetes.
